Terapia-alvo versus dacarbazina no tratamento de primeira linha do melanoma avançado não cirúrgico e metastático: análise de impacto orçamentário na perspectiva do Sistema Único de Saúde, 2018-2020*

Overview of attention for article published in Epidemiologia e Serviços de Saúde, July 2019

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 18 Mendeley

So far, Altmetric has seen 1 X post from an account with 112 followers.

Target therapy versus dacarbazine in first-line treatment of advanced non-surgical and metastatic melanoma: budget impact analysis from the perspective of the Brazilian National Health System, 2018-2020. https://t.co/1AT44VEWwV

05 Jul 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.